Creo Medical Group PLC UK Endoscopy Training Course
October 19 2018 - 2:00AM
RNS Non-Regulatory
TIDMCREO
Creo Medical Group PLC
19 October 2018
Creo Medical Group plc
("Creo" or the "Company")
UK Endoscopy Training Course
Live demonstrations and training using Creo's Speedboat and
CROMA platform
Two-day course supports CREO's UK-wide Clinical Education
Programme
Over 40 Clinicians participating
Creo Medical Group plc (AIM: CREO), a medical device company
focused on the emerging field of surgical endoscopy, announces that
the Queen Elizabeth and the Queen Mother Hospital in Margate ("QEQM
Hospital"), part of the East Kent University Hospitals Foundation
Trust ("East Kent Trust"), today enters into the second day of a
two-day endoscopy training course for over 40 UK clinicians, which
will include live demonstrations and training on Creo's Speedboat
device and CROMA advanced energy platform.
The Endoscopy Training Course is being led by Dr Zacharias
Tsiamoulos, Consultant in Gastroenterology and Specialist in GI
Endoscopy at the East Kent Trust and Professor Yutaka Saito,
Director of the Endoscopy Division at the National Cancer Center
Hospital, Tokyo, Japan.
The course is being sponsored by Creo and Diagmed Healthcare
Limited ("Diagmed"), Creo's UK distribution partner, amongst
others. Dr Tsiamoulos is a key opinion leader in the field of
Gastrointestinal ("GI") therapeutic endoscopy and a leading user of
Creo's Speedboat device for colorectal endoscopic submucosal
dissection, an advanced surgical procedure using endoscopy to
remove gastrointestinal pre-cancerous lesions that have not entered
the muscle layer. Dr Tsiamoulos trained in the procedure in Japan
under world leading key opinion leader, Professor Saito, one of the
global pioneers in therapeutic endoscopy.
The course supports Creo's education-led strategy and reflects
Diagmed's commitment to advance the roll out of Creo's Clinical
Education Programme in the UK, ensuring quality control and best
patient outcomes through the education of key clinicians in the use
of Speedboat and the CROMA platform.
The two-day event will allow delegates to observe a number of
live procedures undertaken by Dr Tsiamoulos using Creo's Speedboat,
which can deliver bipolar radiofrequency for precise localised
cutting and microwave energy for controlled coagulation. Dr
Tsiamoulos will also provide direct training to delegates on the
techniques required to successfully undertake endoscopic submucosal
dissection procedures using the Speedboat device as an outpatient
procedure, helping to reduce the risks associated with alternative
open and laparoscopic procedures, reducing the length of stay in
hospital for the patient, and reducing the cost of treatment and
transferring therapy from the operating theatre to the endoscopy
room.
Craig Gulliford, Chief Executive Officer of Creo, commented:
"Our strategy has always been focused on ensuring that key
clinicians are educated in the use of Speedboat and the CROMA
platform to safeguard quality control and best patient outcomes.
This training course at the QEQM hospital, and our wider Clinical
Education Programme, aims to ensure that the first adopters of our
technology, having been carefully mentored by our own doctors and
endoscopy nurses, can deliver consistently high standards in this
emerging field of surgical endoscopy."
Creo Medical Group plc
Richard Rees (CFO) +44 (0)129 160 6005
Cenkos Securities +44 (0)20 7397 8900
Stephen Keys/Mark Connelly (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Helen Cresswell Mob: +44 (0)7841 917 679
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and RF energy to surgical endoscopy. Creo has
developed CROMA, an electrosurgical advanced energy platform that
combines bipolar radiofrequency for precise localised cutting and
microwave for controlled coagulation. This technology provides
clinicians with flexible, accurate and controlled surgical
solutions.
The Company's strategy is to bring its CROMA platform to market
through a suite of medical devices which the Company has designed,
initially for the emerging field of GI therapeutic endoscopy, an
area with high unmet needs. The CROMA platform will be developed
further for bronchoscopy and laparoscopy procedures. The Company
believes its technology can impact the landscape of surgery and
endoscopy by providing a safer, less-invasive and more
cost-efficient option of treatment.
For more information about Creo Medical please see our website,
investors.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAGDBDGCDBBGIC
(END) Dow Jones Newswires
October 19, 2018 02:00 ET (06:00 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024